Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight

globenewswire.com
AMGN Amgen's investigational siRNA therapy Olpasiran (AMG 890) for ASCVD is in Phase III trials and shows promise in lowering Lp(a) levels, a key contributor to residual ASCVD risk. The company is also mentioned in relation to Maridebart Cafraglutide (MarTtide/AMG 133). ARWR Arrowhead Pharmaceuticals is mentioned as a partner with Amgen for the development of Olpasiran (AMG 890), an investigational ASCVD therapy. No specific sentiment is attributed to Arrowhead directly. IONS Ionis Pharmaceuticals is developing Pelacarsen (TQJ230) in partnership with Novartis. This therapy is highlighted as a late-stage candidate focusing on lipoprotein(a), a key factor in ASCVD risk, indicating positive market potential. NVS Novartis is collaborating with Ionis Pharmaceuticals on Pelacarsen (TQJ230), a late-stage ASCVD therapy targeting lipoprotein(a). This partnership and drug candidate suggest a positive outlook for Novartis in this market segment. NVO Novo Nordisk's investigational monoclonal antibody Ziltivekimab, targeting inflammation in cardiovascular disease, is in Phase III. Encouraging biomarker data suggests potential for this therapy in the ASCVD market. MRK Merck is mentioned for its investigational drug Enlicitide Decanoate (MK-0616) in the ASCVD pipeline. The article lists it among other potential therapies but does not provide specific sentiment or performance indicators. LLY REGN Regeneron Pharmaceuticals is listed as a key company in the PCSK9 inhibitors market and Familial Hypercholesterolemia market reports. No specific drug or sentiment is detailed in the article. ESPR Esperion Therapeutics is mentioned in relation to the Familial Hypercholesterolemia market. The article does not provide specific details or sentiment regarding the company's performance or prospects. ALNY Alnylam Pharmaceuticals is listed as a key company in the PCSK9 Inhibitors market. The article does not provide specific details or sentiment regarding the company's performance or prospects. VRTX Verve Therapeutics is mentioned in relation to the PCSK9 Inhibitors market and Atherosclerosis market reports. No specific drug or sentiment is detailed in the article. XBI

New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight

The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as Olpasiran (AMG 890) (Amgen/Arrowhead Pharmaceuticals), Obicetrapib (TA-8995) (Newamsterdam Pharma/Menarini), Apabetalone (RVX000222) (Resverlogix), Pelacarsen (TQJ230) (Ionis Pharmaceuticals/Novartis), and others, and the increasing prevalence of ASCVD.

DelveInsight’s Atherosclerotic Cardiovascular Disease Market Insights report includes a comprehensive understanding of current treatment practices, emerging atherosclerotic cardiovascular disease drugs, market share of individual therapies, and current and forecasted atherosclerotic cardiovascular disease market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Atherosclerotic Cardiovascular Disease Market Summary

Discover which atherosclerotic cardiovascular disease medications are expected to grab the market share @ Atherosclerotic Cardiovascular Disease Market Report

Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, commented: “While marketed therapies have cemented PCSK9 inhibition as a powerful intervention, uptake challenges have left room for innovation. This gap is now fueling a new wave of competition with oral, long-acting, and gene-editing approaches.”

Key Factors Driving the Growth of the Atherosclerotic Cardiovascular Disease Market

Atherosclerotic Cardiovascular Disease Market Analysis

Learn more role of PCSK9 inhibitors and inclisiran in market growth @ Atherosclerotic Cardiovascular Disease Treatment Market

Atherosclerotic Cardiovascular Disease Competitive Landscape

Some of the drugs in the ASCVD clinical trial landscape include Olpasiran (AMG 890) (Amgen/Arrowhead Pharmaceuticals), Obicetrapib (TA-8995) (Newamsterdam Pharma/Menarini), Apabetalone (RVX000222) (Resverlogix), Pelacarsen (TQJ230) (Ionis Pharmaceuticals/Novartis), Lerodalcibep (LIB-003) (LIB Therapeutics), Laroprovstat (AZD0780) (Astrazeneca), Enlicitide Decanoate (MK-0616) (Merck), Maridebart Cafraglutide (MarTtide/AMG 133) (Amgen), Orforglipron (LY3502970) (Eli Lilly), Muvalaplin (LY3473329) (Eli Lilly), and others.

NewAmsterdam Pharma’s Obicetrapib is a novel, highly selective cholesteryl ester transfer protein (CETP) inhibitor under development for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH). The agent lowers LDL-C by blocking CETP activity, thereby reducing hepatic cholesterol levels, increasing LDL receptor expression, and enhancing LDL clearance. Preclinical studies have shown that CETP inhibition with obicetrapib significantly decreases LDL-C through these mechanisms. The drug is currently being investigated in a Phase III clinical trial.

Amgen’s Olpasiran is an investigational small interfering RNA (siRNA) therapy developed by Amgen for lowering elevated lipoprotein(a) [Lp(a)] levels in adults with ASCVD. It acts via RNA interference to suppress Lp(a) production in hepatocytes by specifically inhibiting its expression. Olpasiran is presently undergoing evaluation in a Phase III clinical trial.

Novo Nordisk’s Ziltivekimab is an investigational monoclonal antibody designed to address inflammation associated with cardiovascular disease by selectively inhibiting interleukin-6 (IL-6), a key pro-inflammatory cytokine. The therapy is currently in Phase III clinical development. Data presented at the American College of Cardiology Scientific Session indicate that ziltivekimab has shown encouraging reductions in multiple inflammatory and thrombotic biomarkers associated with atherosclerosis.

Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, commented: “The ASCVD clinical trial landscape is undergoing a notable transition, moving beyond traditional LDL-C–focused strategies toward more targeted, mechanism-based interventions for cardiovascular risk reduction. The advancement of late-stage candidates such as Amgen’s olpasiran and Ionis/Novartis’ pelacarsen highlights the increasing clinical and commercial emphasis on lipoprotein(a), a genetically determined and long-overlooked contributor to residual ASCVD risk.”

To know more about upcoming therapies expected to reshape ASCVD treatment, visit @ Atherosclerotic Cardiovascular Disease Medication

Recent Developments in the ASCVD Market

What is Atherosclerotic Cardiovascular Disease?

ASCVD is a chronic medical disorder marked by the accumulation of fatty plaques along the inner lining of arteries. These plaques are composed of cholesterol, lipids, calcium, and cellular debris. As they gradually harden and enlarge, they cause the arteries to narrow, restricting blood flow to essential organs and tissues. ASCVD is a progressive condition that can involve multiple vascular beds across the body, including the coronary arteries of the heart, the cerebral arteries of the brain, and the peripheral arteries of the limbs. Its most common clinical forms include Coronary Artery Disease (CAD), cerebrovascular disease such as stroke, and Peripheral Arterial Disease (PAD). In many cases, ASCVD remains asymptomatic until significant arterial narrowing or blockage occurs. When symptoms do develop, they may include chest pain (angina), shortness of breath, myocardial infarction, stroke, limb ischemia associated with PAD, and abdominal pain.

Atherosclerotic Cardiovascular Disease Epidemiology Segmentation

The ASCVD epidemiology section provides insights into the historical and current atherosclerotic cardiovascular disease patient pool and forecasted trends for the leading markets. In the United States, systemic inflammation–associated ASCVD cases were estimated at approximately 17 million in 2024.

The atherosclerotic cardiovascular disease market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

Download the report to understand impact of diabetes/obesity/hypertension on ASCVD burden @ Atherosclerotic Cardiovascular Disease Treatment Options

Scope of the Atherosclerotic Cardiovascular Disease Market Report

Discover more about which companies are leading the ASCVD market and forecasted to grow? @ Atherosclerotic Cardiovascular Disease Clinical Trials

Table of Contents

Related Reports

Atherosclerosis Market

Atherosclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atherosclerosis companies, including Novo Nordisk, Amgen, Merck Sharp & Dohme, Afimmune, Silence Therapeutics, Verve Therapeutics, 858 Therapeutics, Abionyx Pharma, Bitterroot Bio, among others.

Atherosclerosis Clinical Trial Analysis

Atherosclerosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key atherosclerosis companies, including Novo Nordisk, Amgen, Merck Sharp & Dohme, Afimmune, Silence Therapeutics, Verve Therapeutics, 858 Therapeutics, Abionyx Pharma, Bitterroot Bio, among others.

PCSK9 Inhibitors Market

PCSK9 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PCSK9 inhibitors companies, including LIB Therapeutics, Merck, Verve Therapeutics, CiVi Biopharma, Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals, among others.

PCSK9 Inhibitors Clinical Trial Analysis

PCSK9 Inhibitors Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PCSK9 inhibitors companies, including Ionis Pharmaceuticals, Akeso Biopharma, Amgen, Novo Nordisk, Civi BioPharma, among others.

Familial Hypercholesterolemia Market

Familial Hypercholesterolemia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key familial hypercholesterolemia companies, including Sanofi, Regeneron Pharmaceuticals, Amgen, Esperion Therapeutics, Aegerion Pharmaceutical, Esperion Therapeutics, Regeneron Pharmaceuticals, Novartis, LIB Therapeutics, NeuroBo Pharmaceuticals, Arrowhead Pharmaceuticals, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Pharmaceutical Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn| Facebook| Twitter